On August 19, Moderna and Merck jointly unveiled positive topline results from the global Phase III INTerpath-001 study evaluating the individualized neoantigen mRNA therapy intismeran autogene (V940/mRNA-4157). The candidate, combined with pembrolizumab, was tested as an adjuvant treatment for patients with completely resected Stage IIB-IV melanoma. The study successfully met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS). This marks the world's first individualized neoantigen mRNA cancer therapy to achieve positive Phase III results, triggering strong reactions across global capital markets. Moderna's share price surged substantially, prompting a broad value reassessment across the mRNA oncology immunotherapy sector.
From an industry perspective, the significance of this outcome extends far beyond a single product's clinical success. It signals that mRNA technology, following its validation in infectious disease vaccines, has now cleared a crucial clinical validation threshold in cancer treatment. Industry observers believe that over the medium-to-long term, mRNA cancer vaccines are opening a second growth curve for the vaccine industry—moving from prevention to therapy—and pointing the sector toward a hundred-billion-dollar oncology treatment market. The sector's valuation benchmark is expected to shift upward systematically, and the oncology pipelines of domestic mRNA platform companies are also poised for valuation re-rating.
Following the announcement, Moderna's stock climbed sharply, heating up the mRNA oncology immunotherapy track. Market attention quickly pivoted from overseas leaders to innovative drug companies in China with proprietary mRNA technology platforms. Catalyzed by this milestone event, Hong Kong-listed EVEREST MED (HK: 1952) opened significantly higher on August 20, with intraday gains at one point expanding to 89% and reaching a high of HK$45.04.
Forward-looking mRNA Platform Investment Faces Strategic Validation
Over the past few years, mRNA technology demonstrated rapid design and scalable manufacturing capabilities through COVID-19 vaccines. However, whether it could advance from preventive vaccines to therapeutic drugs has remained the industry's core question. This Phase III result delivers the most compelling answer to date. The overseas breakthrough has also brought domestic companies' strategic positioning back into the market's spotlight, with Chinese players now coming into view.
EVEREST MED is among a small group of biopharmaceutical companies globally possessing a fully integrated, independently controlled mRNA technology platform. With forward-looking investments in this field, the company has built a diversified R&D pipeline spanning tumor therapeutic vaccines and mRNA-based in vivo CAR-T approaches, positioning it at the forefront of mRNA oncology innovation in China. As one of the most clinically advanced domestic companies pursuing the personalized neoantigen pathway, EVEREST MED's individualized tumor therapeutic vaccine EVM16 remains in Phase Ia, a clinical-stage gap compared to Moderna's mRNA-4157. However, this gap primarily reflects differences in development progress rather than platform capabilities.
EVEREST MED's mRNA platform features self-developed and continuously iterative capabilities, having established end-to-end platform competencies covering antigen design, mRNA sequence optimization, LNP delivery, and commercial-scale manufacturing. Built on its proprietary R&D system, the company's AI algorithm platform has undergone four iterations. It has also established and continuously optimized its proprietary LNP delivery platform, with patent positioning in ionizable lipids and stealth lipids. The internal proprietary lipid library now exceeds 600 molecules, sustainably supporting the development of mRNA drugs across various indications and antigen types. This platform is far from a conceptual initiative—it has already received clinical validation through COVID-19 vaccine development. In a global Phase II head-to-head study, the PTX-COVID19-B vaccine developed on this platform demonstrated immunogenicity non-inferiority against Pfizer/BioNTech's Comirnaty vaccine. Among 374 subjects receiving two doses of PTX-COVID19-B, neutralizing antibody titers (GMT) at two weeks post-vaccination achieved statistical non-inferiority compared to Comirnaty. Additionally, PTX-COVID19-B was generally well tolerated, with safety and tolerability profiles similar to Comirnaty.
mRNA Platform Drives Multi-Pathway Development, Tumor Vaccines Enter Clinical Validation Stage
Leveraging its proprietary AI-plus-mRNA platform, EVEREST MED has formed a multi-pathway R&D structure covering universal tumor-associated antigen (TAA) vaccines, personalized tumor neoantigen vaccines, and mRNA-based in vivo CAR-T approaches among other frontier areas. EVM16 shares the same personalized neoantigen vaccine pathway as Moderna's intismeran autogene (V940/mRNA-4157). EVM16 has completed its first-in-human clinical data readout. A multi-tumor-type IIT study showed that even in patients with very advanced tumors, EVM16 could induce immunogenicity, with individual cases of stable disease (SD) and partial response (PR) observed as clinical signals. The relevant IIT Phase Ia data were presented at the 2026 AACR Annual Meeting, demonstrating dose-dependent immunogenicity, positive preliminary efficacy signals, and favorable safety and tolerability in late-line cancer patients. The company plans to initiate the IIT Phase Ib clinical study in the fourth quarter of 2026.
Moderna's clinical breakthrough has established its first-mover advantage in mRNA cancer vaccines, but this track is far from settled. BioNTech has also shown encouraging early data in pancreatic cancer (autogene cevumeran combined with chemotherapy plus PD-1, with significantly prolonged median RFS in Phase II). Furthermore, its universal product BNT113, targeting unresectable, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC), has advanced to Phase III. This indicates that both personalized and universal pathways are clinically viable.
Unlike personalized vaccines that require custom manufacturing for each patient, EVEREST MED's EVM14, as a universal off-the-shelf tumor therapeutic vaccine, offers significant cost and accessibility advantages applicable to multiple tumor types. EVM14 received IND approvals from the U.S. FDA and China's drug regulator in 2025. The U.S. Phase I study has enrolled its first patient, with clinical development in China progressing in parallel. Additionally, the immunomodulatory vaccine EVM15 has entered the PCC (preclinical candidate confirmation) stage, potentially further expanding the mRNA platform's applications in tumor immunotherapy. The in vivo CAR-T project EVM18 has also initiated an IIT study targeting autoimmune diseases, while the dual-target project EVM20 is steadily advancing clinical development.
Dual-Engine Strategy Deepens, Self-Development Capabilities Take Center Stage
Moderna's landmark Phase III breakthrough provides a direct industry benchmark for EVEREST MED's strategic positioning in mRNA cancer vaccines, while also making its self-development capabilities more visible to the market. EVEREST MED is forging a dual-engine capability structure combining business development partnerships and proprietary R&D, with the mRNA technology platform standing as a key outcome of this strategy.
Notably, EVEREST MED recently released its 2026 interim results. The financial report shows the company achieved total revenue of RMB 1.148 billion in the first half of the year, a year-on-year increase of 157%. Non-IFRS adjusted profit reached RMB 97.23 million, successfully turning profitable. Core product Nefecon generated sales of RMB 889 million in the first half. Meanwhile, the company is transitioning from a single-blockbuster-driven model to a 3.0 development stage characterized by multi-therapeutic-area, multi-pipeline synergy. As a key pillar of its proprietary R&D system, the mRNA platform is well-positioned to continuously release growth momentum in the new era of tumor immunotherapy.